登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
ClinicalTrials.gov 上登记的一项B 细胞急性淋巴细胞白血病开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06718244,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
16 岁 至 70 岁;性别:不限
登记记录的入选字段
Newly diagnosed Ph-negative B-ALL, MRD positive(bone marrow MRD ≥0.01% by flow cytometry) in CR1 (with <5% blasts in bone marrow, no blasts in peripheral blood, no extramedullary disease)after induction chemotherapy or consolidation chemotherapy.
入选标准第 3 条
ECOG score of 0-1 at screening
入选标准第 2 条
Aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN);
入选标准第 7 条
Alanine aminotransferase (ALT) ≤3 times ULN;
入选标准第 8 条
Total bilirubin ≤2 times ULN (for patients with Gilbert's syndrome, total bilirubin ≤3.0 times ULN and direct bilirubin ≤1.5 times ULN);
入选标准第 9 条
Serum creatinine ≤1.5 times ULN, or creatinine clearance ≥60 mL/min (using the Cockcroft-Gault formula);
入选标准第 10 条
International Normalized Ratio (INR) ≤1.5 times ULN and activated partial thromboplastin time (APTT) ≤1.5 times ULN;
入选标准第 11 条
HBe-Ab and/or HBc-Ab positive with HBV-DNA levels above the lower limit of quantification;
排除标准第 6 条
HCV-Ab positive;
排除标准第 7 条
HIV antibody positive;
排除标准第 9 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06718244,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age between ≥16 and ≤70 years at screening, no gender restrictions ECOG score of 0-1 at screening Newly diagnosed Ph-negative B-ALL, MRD positive(bone marrow MRD ≥0.01% by flow cytometry) in CR1 (with <5% blasts in bone marrow, no blasts in peripheral blood, no extramedullary disease)after induction chemotherapy or consolidation chemotherapy. Newly diagnosed Ph-positive B-ALL, MRD positive(bone marrow MRD ≥0.01% by flow cytometry or BCR-ABL1 >0.01% detected by qPCR) in CR1 (with <5% blasts in bone marrow, no blasts in peripheral blood, no extramedullary disease) . At diagnosis of B-ALL,CD19 expression of leukemic cells is positive by flow cytometry in bone marrow or peripheral blood. Appropirate organ function, meeting the following criteria: Aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) ≤3 times ULN; Total bilirubin ≤2 times ULN (for patients with Gilbert's syndrome, total bilirubin ≤3.0 times ULN and direct bilirubin ≤1.5 times ULN); Serum creatinine ≤1.5 times ULN, or creatinine clearance ≥60 mL/min (using the Cockcroft-Gault formula); International Normalized Ratio (INR) ≤1.5 times ULN and activated partial thromboplastin time (APTT) ≤1.5 times ULN; Left ventricular ejection fraction (LVEF) ≥50%; Minimum pulmonary reserve, with oxygen saturation >91% on room air; Meets leukapheresis standard of the study center, with no contraindications for blood cell separation; Voluntarily agrees to participate in this study and signs on the informed consent form(ICF).排除标准:Exclusion Criteria:
Received CAR-T cell therapy before screening; Inherited bone marrow failure syndrome(IBMFS) or any other known bone marrow failure syndromes; Active systemic autoimmune diseases requiring treatment; Any of the following conditions: HBsAg and/or HBeAg positive; HBe-Ab and/or HBc-Ab positive with HBV-DNA levels above the lower limit of quantification; HCV-Ab positive; TP-Ab positive; HIV antibody positive; EBV-DNA or CMV-DNA levels above the lower limit of quantification; Active infection at screening. Any other malignancy within the past five years before screening, excluding cases where the patient has been disease-free for more than 5 years after curative treatment or has a low risk of relapse as assessed by the investigator; Any of the following cardiac conditions: NYHA Class III or IV congestive heart failure; Severe arrhythmia requiring treatment; Uncontrolled hypertension or pulmonary hypertension despite standard therapy; Unstable angina; Myocardial infarction, bypass surgery, or stent placement within six months before cell retransfusion; Clinically significant valvular disease; Other cardiac conditions deemed unsuitable by the investigator; History of epilepsy, cerebellar disease, or other active central nervous system disorders; Uncontrolled diabetes; History of symptomatic deep vein thrombosis or pulmonary embolism within six months before screening that is not well controlled; History of hypersensitivity to any component of the investigational product. Received a live vaccine within six weeks before screening; Life expectancy of less than three months; Participation in another interventional clinical trial and receiving investigational drugs within three months (for unapproved drugs) or within five half-lives (for approved drugs) before cell infusion, or plans to participate in another clinical trial or receive anti-cancer therapy outside the study protocol during the study period; Other conditions deemed unsuitable for participation in this clinical trial by the investigator.
引自 ClinicalTrials.gov, NCT06718244, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06718244,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。